Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16483012 | 0.81 | CYP3A4 (0.34) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL7456451 | 0.78 | RAPGEF4 (0.39) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL23845284 | 0.78 | HMGCR (0.36) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL2839922 | 0.77 | CYP3A4 (0.52) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL29087671 | 0.72 | ACHE (0.34) | FFAR4 | |
| SCHEMBL13550039 | 0.71 | CYP3A4 (0.37) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL1484477 | 0.71 | GPR35 (0.35) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL954081 | 0.70 | RAPGEF4 (0.35) | RAPGEF4 | |
| SCHEMBL8237570 | 0.70 | RAPGEF4 (0.45) | RAPGEF4CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL13550149 | 0.70 | CYP3A4 (0.40) | RAPGEF4CYP3A4CHRM1ALOX15MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8629125-B2 | Inhibitors of fatty acid amide hydrolase | Infinty Pharmaceuticals, Inc. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130059819-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-8329675-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2404607-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2399585-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2399584-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| CN-101563089-A | Boronic acids and esters as inhibitors of fatty amide hydrolase | INFINITY DISCOVERY INC (US) | 2009-10-21 | — | — | CN | disclosed |
| EP-2073816-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | RAPGEF4 1470/4885CYP3A4 1007/4885CHRM1 3479/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | RAPGEF4 1470/4885CYP3A4 1007/4885CHRM1 3479/4885 |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | FAAH, FAAH2, ASAH1 | RAPGEF4 1454/4885CYP3A4 929/4885CHRM1 2984/4885 |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | RAPGEF4 1470/4885CYP3A4 1007/4885CHRM1 3479/4885 |
| US-20130059819-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | RAPGEF4 1470/4885CYP3A4 1007/4885CHRM1 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.